A Study to Evaluate the Effect of KarXT on Urological Safety
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07221877
- Phase
- PHASE4
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Xanomeline/trospium chloride — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
Key Dates
- Start date
- Jan 20, 2026
- Status verified
- Jun 2026
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2027
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: KarXT
Primary Outcome Measure
Change from baseline in voiding dynamics (Qmax) over time [ Time Frame: Up to 12 months ]
Central Contacts
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
- First line of the email MUST contain NCT # and Site #.
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Pillar Clinical Research- Little Rock | Little Rock | Arkansas | 72204 | Leslie Smith, Site 0017 501-350-3285 |
| Clinical Innovations, Inc. dba CITrials | Bellflower | California | 90706 | Robert Bota, Site 0007 562-748-4999 |
| CenExel CNS - Garden Grove | Garden Grove | California | 92845 | David Walling, Site 0006 714-799-7799 |
| ATP Clinical Research | Orange | California | 92866 | Gustavo Alva, Site 0016 949-354-5353 |
| Innovative Clinical Research | Lauderhill | Florida | 33319 | Rishi Kakar, Site 0003 786-512-4106 |
| Health Synergy Clinical Research | West Palm Beach | Florida | 33407 | Mohammad Nisar, Site 0004 786-831-7303 |
| Pillar Clinical Research -Chicago | Chicago | Illinois | 60641 | Roueen Rafeyan, Site 0010 312-865-6336 |
| Uptown Research Institute | Chicago | Illinois | 60640 | John Sonnenberg, Site 0005 773-968-9868 |
| IMA Clinical Research Las Vegas | Las Vegas | Nevada | 89102 | Mustafa Rawaf, Site 0013 702-527-7401 |
| Hassman Research Institute Marlton Site | Marlton | New Jersey | 08053 | Elan Cohen, Site 0002 267-981-8911 |
| Adams Clinical Philadelphia | Philadelphia | Pennsylvania | 19104 | Cassie Blanchard, Site 0014 631-252-0769 |
| Local Institution - 0001 | Austin | Texas | 78754 | Site 0001 |
| InSite Clinical Research | DeSoto | Texas | 75115 | Benji Kurian, Site 0015 214-497-3151 |
Find similar trials in Little Rock, AR
By condition
By specialty
Related Studies
- Zyprexa® Relprevv™ Patient Care ProgramEnrolling By Invitation · Eli Lilly and Company · Blue Bell, Pennsylvania
- Database Registry for Neural Network Biomarkers in PsychosisRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as CorrelatesPHASE4 · Recruiting · Corporal Michael J. Crescenz VA Medical Center · Philadelphia, Pennsylvania
- Bromocriptine for Patients With Schizophrenia and PrediabetesPHASE4 · Not Yet Recruiting · VA Pittsburgh Healthcare System · Pittsburgh, Pennsylvania